Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
SEC Accession No. 0001558370-19-003265
Filing Date
2019-04-25
Accepted
2019-04-25 07:10:58
Documents
5
Effectiveness Date
2019-04-25

Document Format Files

Seq Description Document Type Size
1 DEFA14A defa14a.htm DEFA14A 45387
2 GRAPHIC defa14ag001.jpg GRAPHIC 71056
3 GRAPHIC defa14ag002.jpg GRAPHIC 122809
4 GRAPHIC defa14ag003.jpg GRAPHIC 28490
5 GRAPHIC defa14ag004.jpg GRAPHIC 12289
  Complete submission text file 0001558370-19-003265.txt   369997
Mailing Address 640 LEE ROAD SUITE 200 WAYNE PA 19087
Business Address 640 LEE ROAD SUITE 200 WAYNE PA 19087 484-324-7933
Aclaris Therapeutics, Inc. (Filer) CIK: 0001557746 (see all company filings)

EIN.: 460571712 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEFA14A | Act: 34 | File No.: 001-37581 | Film No.: 19765341
SIC: 2834 Pharmaceutical Preparations